NCT02530905View on ClinicalTrials.gov

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 8, 2015

Primary Completion Date

October 3, 2018

Study Completion Date

October 3, 2018

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

SRP-4045

SRP-4045 solution for IV infusion.

DRUG

Placebo

SRP-4045 placebo-matching solution for IV infusion.

Trial Locations (3)

21205

Kennedy Krieger Institute, Baltimore

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

90095

David Geffen School of Medicine at UCLA, Los Angeles

All Listed Sponsors

lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT02530905 - Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients | Biotech Hunter | Biotech Hunter